Introduction to Medication-Assisted Treatment

Erin Zerbo, MD


Assistant Professor of Psychiatry, Rutgers NJMS

Director, Northern NJ Center of Excellence in MAT

Reward Pathway

- Neurons start in the midbrain
 → release dopamine in the nucleus accumbens
- Baseline: steady dopamine
- Drugs: burst of dopamine (pleasure/salience/motivation)

Responsible for "hedonic tone"




What is Hedonic Tone?

- Sense of well-being, happiness, pleasure, contentment
- "Set" in the reward pathway
- Range: Euphoria $\leftarrow \rightarrow$ Dysphoria
- Altered by psychoactive activities/substances
- Reward Deficiency Syndrome?
 - Kenneth Blum: DRD2 allele \rightarrow lower D2




Natural Rewards and Dopamine Levels




Adapted from: Di Chiara et al, *Neuroscience*, 1999 Adapted from: Fiorino and Phillips, *J Neuroscience*, 1997

Effects of Drugs on Dopamine Levels



Adapted from: Di Chiara and Imperato, Proceedings of the National Academy of Sciences USA, 1988; courtesy of Nora D Volkow, MD


Effects of Drugs on Dopamine Levels



Adapted from: Di Chiara and Imperato, Proceedings of the National Academy of Sciences USA, 1988; courtesy of Nora D Volkow, MD

Acute drug effects

- Extra dopamine release \rightarrow changes in cell signaling
 - D1 DA receptor stimulation →
 cAMP-dependent protein kinase (PKA) →
 phosphorylation of CREB →
 immediate early gene products such as cFos →
 short-term neuroplastic changes for a few hrs/days



... but none of this explains long-lasting behavioral changes

How to explain end-stage addiction?

Overwhelming desire to obtain drug

Diminished ability to control drug seeking


Reduced pleasure from biological rewards

End-stage addiction is mostly about waiting for the police, or someone, to come and bury you in your shame.

meetville.com

David Carr

Transition to addiction




Repeated use \rightarrow brain changes that last for <u>days-weeks</u>

- Long-acting proteins involved
 - $\Delta FosB = transcriptional regulator,$


increases AMPA glutamate receptor subunits

Create new circuits based on <u>glutamate</u>, not dopamine



New circuits created from prefrontal cortex (glutamate)

Circuits Involved In Drug Abuse and Addiction



All of these brain regions must be considered in developing strategies to effectively treat addiction NIDA


And to make matters worse... **Dopamine D2 Receptors are Decreased by Addiction**













DA D2 Receptor Availability



Volkow ND, Baler RD. Addiction science: Uncovering neurobiological complexity. Neuropharmacology 2014;76:235-49.



Blue = mature state



What environmental factors make us vulnerable to addiction?

dopamine D2 receptor — the DRD2 gene). Concomitantly, environmental factors such as stress (high stress combined with polymorphisms in dopaminergic genes, as well as other neurotransmitter genetic variants), and social defeat also alter brain-reward mechanisms in such a manner as to impart vulnerability to addiction [7]. Thus, elevated stress levels,

stress & social defeat (interacting with our genes)

Blum K, Gardner E, Oscar-Berman M, et al. "Liking" and "Wanting" Linked to Reward Deficiency Syndrome (RSD). Curr Pharm Des 2012.

Transformative Spiritual Experience



"We've been doing this for over 40 years since Nixon... The drugs are more available, purer quality, and cheaper than they've ever been before... and we've destroyed more lives than drugs have by incarcerating people, hanging felony convictions on them, denying them education, denying them jobs... And we don't even have one drug-free prison in America."

- Retired police captain Peter Christ







InSite in Vancouver: An overdose prevention center (i.e., a safe injection site)

BEFORE DCR

AFTER DCR

Make money. Buy street heroin. Hide from the police. Find or share needle. Use puddle water. Rush to inject while keeping a look out. Throw drug paraphernalia on the ground. Repeat.


Life of people who use drugs before and after the opening of DCR's

Make money. Buy street heroin . Visit DCR. Receive hygienic paraphernalia (syringe, cookers, filter, alcohol pad). Use under supervision of trained professional first aid. Properly dispose of drug paraphernalia in biohazard containers. Relax, take a shower, change clothes, talk to a social worker & organise the rest of my day.

Courtesy of InSite


Opioids

Endogenous vs. Exogenous Opioids




Classification of Opioids

Traditional	Origin	Function
<u>Strong</u> morphine fentanyl	Naturally occurring morphine, codeine, thebaine	<u>Pure agonists</u> morphine, fentanyl, remifentanil
remifentanil Intermediate buprenorphine	<u>Semisynthetic</u> oxycodone, hydrocodone, hydromorphone, buprenorphine	Partial agonist buprenorphine
pentazocine butorphanol <u>Weak</u> codeine	Synthetic fentanyl methadone tramadol	Agonists-antagonists pentazocine nalbuphine Pure antagonists naloxone naltrexone



Distress and Pain: Dorsal Anterior Cingulate Cortex




- 🔵 Pain
- Social rejection
- 🔴 Hunger
- 😑 Thirst
- Breathlessness

Opioid Intoxication

• Euphoria experienced as a "rush" of intensely pleasurable feelings

- Reduced psychological pain:
 - Anxiety, depression, anger, paranoid ideation/psychosis


- GI: nausea, vomiting, constipation
- Miosis (pinpoint pupils)
- Respiratory suppression



Opioid Withdrawal



- Dysphoric mood
 Nausea/vomiting
 Muscle aches
 Lacrimation
 Rhinorrhea
 Pupil dilation
 - Pilorection
 - Sweating
 - Diarrhea
 - Yawning
 - Fever
 - Insomnia





2 mL single-dose NDC 0409-90 LV. or L.M. use Fentanyl Citrate Inj., USP 100 mcg Fentanyl/2 mL (50 mcg/mL)

RL-S


Respire, Inc. Lake Forest, IL 60045 USA 2 mL Single-dose NDC 0409-8 I.V. or I.M. use Fentanyl Citrate Inj., USP 100 mcg Fentanyl/2 mL (50 mcg/mL)

RL-

Hospira, Inc. Lake Forest, IL 60045 USA

Treatment





Acute withdrawal

- 7 days for heroin
- Up to 25 days for methadone

Post-Acute Withdrawal Syndrome (PAWS)

Can be up to 1 year

Post-Acute Withdrawal Syndrome (PAWS)

- Alcohol or drug cravings
- Irritability
- Anxiety
- Presence of a dysphoria state or depression
- Trouble sleeping
- Decreased ability to feel pleasure (anhedonia)
- Decreased libido (interest in sex)
- A reduction in short-term memory
- Chronic and lasting fatigue
- Struggling to concentrate
- Difficulty focusing on tasks
- Impaired decision-making skills
- Reduced control of executive functions
- Physical problems, especially pain, that may not be attributed to a specific cause



HUFFPOST

THE BLOG 08/27/2013 02:56 pm ET | Updated Oct 27, 2013

Death by Detoxification


By Adam Bisaga, M.D., Maria A. Sullivan, M.D., Ph.D.

Hardly a day passes when we do not hear reports from many different areas of the country about young people dying from overdoses of narcotics. The recent death of the actor Cory Monteith was a stark public reminder of this recurring tragedy. Many of these incidents are even more tragic since they happen not too long after discharge from a treatment program. These headlines are a wake-up call: What more can be done to save the lives of young people with drug addictions, especially those who come to us seeking help?

Monteith was taking heroin, but we know that taking opioid painkillers — such as Vicodin or Oxycontin — affect the brain similarly to heroin and could have resulted in the same tragic outcome. He died of an overdose, a leading cause of death in individuals who use heroin or misuse painkillers. Overdoses, which are most often unintentional, are too common among people who regularly use heroin or misuse painkillers. Drug overdose death rates in the U.S. have more than tripled since 1990. In the past decade, deaths from opioids have surpassed motor vehicles as a cause of death in some states.

Benefits of MAT: Decreased Mortality

Death rates:



Standardized Mortality Ratio

Dupouv et al., 2017 Evans et al., 2015 Sordo et al., 2017

The NEW ENGLAND JOURNAL of MEDICINE

SPECIAL ARTICLE

129 times the overdose death risk as compared to gen. pop.

Release from Prison — A High Risk of Death for Former Inmates

Ingrid A. Binswanger, M.D., Marc F. Stern, M.D., Richard A. Deyo, M.D., Patrick J. Heagerty, Ph.D., Allen Cheadle, Ph.D., Joann G. Elmore, M.D., and Thomas D. Koepsell, M.D.

ABSTRACT

BACKGROUND

The U.S. population of former prison inmates is large and growing. The period immediately after release may be challenging for former inmates and may involve substantial health risks. We studied the risk of death among former inmates soon after their release from Washington State prisons.

METHODS

We conducted a retrospective cohort study of all inmates released from the Washing-

From the Puget Sound Veterans Affairs Medical Center, Seattle (I.A.B., T.D.K.); the Departments of Medicine (I.A.B., R.A.D., J.G.E.), Health Services (I.A.B., R.A.D., A.C., T.D.K.), Biostatistics (PJ.H.), and Epidemiology (J.G.E., T.D.K.), University of Washington, Seattle; the Department of Medicine, University of Colorado at Denver and the Health Sciences Center, Denver (I.A.B.);

other state residents, with a markedly elevated relative risk of death from drug overdose (129; 95% CI, 89 to 186). The leading causes of death among former inmates

RESULTS

Of 30,237 released inmates, 443 died during a mean follow-up period of 1.9 years. The overall mortality rate was 777 deaths per 100,000 person-years. The adjusted risk of death among former inmates was 3.5 times that among other state residents (95% confidence interval [CI], 3.2 to 3.8). During the first 2 weeks after release, the risk of death among former inmates was 12.7 (95% CI, 9.2 to 17.4) times that among other state residents, with a markedly elevated relative risk of death from drug overdose (129; 95% CI, 89 to 186). The leading causes of death among former inmates were drug overdose, cardiovascular disease, homicide, and suicide.

N Engl J Med 2007;356:157-65. Copyright © 2007 Massachusetts Medical Society.





➢Methadone

Buprenorphine

>Naltrexone

Why do methadone and buprenorphine work?





Volkow Koob 2016 NEJM



When you're dope sick AF and your plug finally calls back after you've already taken your sub



Methadone





Methadose Methadone IR Tablets Mallinckrodt

Buprenorphine





Buprenorphine / Naloxone Tablets Photo by Psych0naut. © 2010 Erowid.org



XR-Naltrexone 380mg IM every 4 weeks



Vivitrol injection preparation - YouTube https://www.youtube.com/watch?v=IZBaDCIWSwg ▼

The Duration Dilemma

RESEARCH

Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies

Luis Sordo,^{1,2,3} Gregorio Barrio,⁴ Maria J Bravo,^{1,2} B Iciar Indave,^{1,2} Louisa Degenhardt,^{5,6} Lucas Wiessing,⁷ Marica Ferri,⁷ Roberto Pastor-Barriuso^{1,2}

¹National Centre for Epidemiology, Carlos III Institute of Health, Madrid, Spain

²Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain

³Department of Preventive Medicine and Public Health, Faculty of Medicine, Complutense University, Madrid, Spain ⁴National School of Public

ABSTRACT

OBJECTIVE

To compare the risk for all cause and overdose mortality in people with opioid dependence during and after substitution treatment with methadone or buprenorphine and to characterise trends in risk of mortality after initiation and cessation of treatment.

INCO

DESIGN


Systematic review and meta-analysis.

DATA SOURCES

out of buprenorphine treatment (2.20, 1.34 to 3.61). In pooled trend analysis, all cause mortality dropped sharply over the first four weeks of methadone treatment and decreased gradually two weeks after leaving treatment. All cause mortality remained stable during induction and remaining time on buprenorphine treatment. Overdose mortality evolved similarly, with pooled overdose mortality rates of 2.6 and 12.7 per 1000 person years in and out of methadone treatment (unadjusted out-to-in rate ratio 4.80, 2.90 to 7.96) and 1.4 and 4.6 in and out of buprenorphine treatment.

The Duration Dilemma

	WHAT IS ALREADY KNOWN ON THIS TOPIC Opioid substitution treatment is effective in suppressing illicit opioid use and reducing all cause and overdose mortality Growing evidence suggests that mortality during and after opioid substitution treatment is time varying and differs by type of drug	RESEARCH nent:
	WHAT THIS STUDY ADDS	
	In patients using methadone maintenance treatment there are, on average, 25 fewer deaths/1000 person years than in patients who discontinue it. Mortality risk	t, ^{5,6}
¹ National Centre for Epidemiology, Carlos III	among opioid users during treatment is less than a third of that expected in the absence of opioid substitution treatment	1.34 to 3.61). In lity dropped
of Health, Madrid, Spain ² Consortium for Biomed	Buprenorphine maintenance treatment is probably also effective in reducing mortality in opioid users, but quantification of averted deaths requires further studies	thadone o weeks after
Research in Epidemiolo; Public Health (CIBERESF Madrid, Spain	The mortality risk in the induction phase of methadone (first four weeks) is high but	remained stable on buprenorphine
³ Department of Preventi Medicine and Public He Faculty of Medicine,	seems to decreases substantially during this period, with a further stabilisation at around six deaths/1000 person years in the remaining time in treatment. This did	l similarly, with and 12.7 per Idone treatment
Complutense University Madrid, Spain ⁴ National School of Pub	not occur with buprenorphine. The mortality risk in the four weeks immediately after cessation of either treatment is high and could exceed 30 deaths/1000 person years	2.90 to 7.96) and the treatment.



Kakko et al, 2003

If you do detox...



When prescribing MAT...



MAT: A Summary

1) Methadone

- Federally-regulated methadone maintenance programs (1970s)
- Decreases overdose deaths, improves psychosocial adjustment, reduces criminal activity, decreases rates of HIV/HCV

2) **Buprenorphine**

8mg BID

- Similar outcomes as for methadone
- Used since 2002
- DATA 2000 waiver allows office-based prescriptions

3) XR- Naltrexone (Vivitrol[®] injection) 380mg IM q 4 wks

- Opioid antagonist (blocks receptor)
- Much less evidence

80 - 120mg daily

Opioids Are Different

 Post-acute withdrawal syndrome → high relapse rates (we need our endogenous opiates)

- Detoxification doesn't work
- Overdose death most likely after period of abstinence
 - Inpatient rehab
 - Incarceration

 \bullet MAT is the gold standard of treatment



JTGERS

New Jersey Medical School Department of Psychiatry

BUPRENORPHINE TRAINING COURSE

This conference is designed to meet the requirement for a buprenorphine waiver certification under the DATA 2000 federal law. Participants will learn about opioid use disorder and how to prescribe buprenorphine for their patients.

Training is FREE and includes complimentary breakfast, lunch and CMEs

Registration

Friday, Sept 27, 2019

CLICK below to Register All Courses are 8:30 am to 3:00 pm Newark, NJ Friday, April 19, 2019 **Rutgers New Jersey** Medical School Park Ridge, NJ Friday, May 10, 2019 Park Ridge Marriott Somerset, NJ Friday, July 12, 2019 **RWJ University** Hospital Somerset Union, NJ Friday, July 19, 2019 Hill Golf Course Ringoes, NJ Friday, August 2, 2019 Heron Glenn Golf and Restaurant Old Bridge, NJ Friday, August 23, 2019 Grand Marguis



Whippany, NJ

Hanover Marriott

Department of Psychiatry, Rutgers New Jersey Medical School Erin Zerbo, MD

You may be eligible to receive

financia

reimbursement

Petros Levounis, MD, MA

Professor and Chair,



Medical School * This training is for Physicians, Physician Assistants and

Advanced Practice Nurses. Eligible providers who complete this full day training and attain the DATA 2000 waiver may be eligible to receive financial reimbursement of \$750.


RUTGERS University Behavioral Health Care (732) 235-9290 NJMS.Rutgers.edu/Psychiatry

This program is funded by the New Jersey Department of Human Services. Funding for this initiative was made possible (in part) by grant no. 5U79TI026556-03 from the Substance Abuse and Mental Health Services Administration (SAMHSA). The American Academy of Addiction Psychiatry (AAAP) is the Data Sponsor for this training. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the NJ Department of Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

Friday, September 27, 2019

NJMS.Rutgers.edu/Psychiatry

The New Jersey MATrx



STATE OF NEW JERSEY

Department of Human Services Division of Mental Health and Addiction Services


ADDICTION SERVICES TREATMENT DIRECTORY

Carole Johnson Commissioner Department of Human Services (DHS) Valerie Mielke

Assistant Commissioner Division of Mental Health and Addiction Services (DMHAS)

Home

In an emergency, always call 911. For 24/7 help finding treatment, please contact 1-844-REACHNJ (1-844-732-2465).



njsams.rutgers.edu/TreatmentDirectory

Northern COE Counties



Please reach out to us!

Northern: <u>COE@njms.rutgers.edu</u>

Southern: <u>SouthernNJCOE@rowan.edu</u>

MAT Provider Hotline 866-221-2611 (Monday - Friday, 8am - 8pm)